Financials data is unavailable for this security.
View more
Year on year Noile-Immune Biotech Inc 's revenues fell -49.37% from 625.78m to 316.82m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 386.62m to a larger loss of 1.13bn.
Gross margin | 99.80% |
---|---|
Net profit margin | -318.08% |
Operating margin | -316.73% |
Return on assets | -17.47% |
---|---|
Return on equity | -17.91% |
Return on investment | -17.90% |
More ▼
Cash flow in JPYView more
In 2023, Noile-Immune Biotech Inc increased its cash reserves by 22.89%, or 1.03bn. Cash Flow from Financing totalled 1.91bn or 603.84% of revenues. In addition the company used 873.08m for operations while cash used for investing totalled 5.32m.
Cash flow per share | -14.77 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 115.62 |
---|---|
Tangible book value per share | 115.62 |
More ▼
Balance sheet in JPYView more
Current ratio | 66.55 |
---|---|
Quick ratio | 66.40 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼